Archive for September, 2012

Forest Laboratories files for FDA approval of new antidepressant drug

Forest Laboratories has filed for marketing approval from the Food and Drug Administration (FDA) for its new antidepressant drug levomilnacipran, which is in the same class of drugs as the antidepressant Effexor. The drugs are classified as serotonin norepinephrine reuptake inhibitors (SNRIs).

Read more about the new SNRI antidepressant drug…

Blood test for inflammation may aid in depression treatment

British scientists from King’s College London’s Institute of Psychiatry have conducted a study matching biological markers in the blood to the best treatments for depression. The study included selective serotonin reuptake inhibitor (SSRI) antidepressants such as Lexapro, Seroplex, and Cipralex, as well as a selection of tricyclic antidepressants.

Read more about the depression treatment study…

SSRIs among most-prescribed drugs in 2011 despite risks

Antidepressant drugs in a class known as selective serotonin reuptake inhibitors (SSRIs) were among the most-prescribed drugs in 2011, despite warnings of potentially serious side effects. Celexa and Zoloft topped the list of SSRI antidepressants prescribed, which totaled more than 264 million.

Read more about the risks associated with SSRI antidepressants…

Bayer seeking European approval for more hormonal birth control

Bayer Pharmaceuticals, the drug maker responsible for Yaz and Yasmin, is seeking European approval for a new hormonal birth control patch. The company’s birth control patch would rival Johnson & Johnson’s Ortho Evra patch, a drug which has come under fire for potential increased risks of blood clots.

Read more about Bayer’s new hormonal birth control patch…

Drug maker receives approval for generic Lexapro

Indian drug maker Lupin Pharmaceuticals has received final approval from the Food and Drug Administration to sell its generic form of the antidepressant Lexapro in the U.S. The company is among the first to receive approval.

Read more about the generic form of Lexapro…

FDA-approved diet drug Qsymia now available with prescription

A new diet drug approved by the U.S. Food and Drug Administration in July is now available for obese and at-risk overweight patients. The oral medication Qsymia can only be obtained with a doctor’s prescription. One of the ingredients in Qsymia is topiramate, an anti-convulsant that has been linked to birth defects such as cleft lip and cleft palate in babies born to women who have taken it for migraines or seizures.

Read more about the potential side effects of Qsymia…

Pfizer’s Wyeth ordered to face class-action over Pristiq

A federal judge has granted class-action status to former Wyeth Inc shareholders who accused the company, now part of Pfizer Inc, of misleading them about risks associated with the antidepressant Pristiq. Analysts once hoped the drug, whose chemical name is desvenlafaxine, could generate more than $2 billion of annual sales, and help Wyeth withstand the 2010 loss of patent protection for its anti-depression drug Effexor.

Read more about Wyeth’s alleged Pristiq misrepresentations…


Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 434 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.